Terumo : Announces Voting Results for the Election of Directors

Press Release

Terumo Announces Voting Results for the Election of Directors

TOKYO, JAPAN - June 27, 2023 - Terumo Corporation (TSE: 4543) hereby announces the voting results for the election of directors held at the Annual General Meeting of Shareholders today. All candidates listed on the May 15 announcement were elected as directors of Terumo Corporation.

1. Directors

(Excluding directors who serve as Audit and Supervisory Committee

Members)

Name		New position		Current position
Toshiaki Takagi		Chairman of the Board		Same as on the left
Shinjiro Sato		President and CEO		Same as on the left
Shoji Hatano		Director and Group Senior Managing Executive		Same as on the left
	Officer
Kazunori Hirose		Director and Group Managing Executive Officer		Same as on the left
Norimasa Kunimoto		Director and Group Managing Executive Officer		Group Managing
		Executive Officer
Yukiko Kuroda		Independent Director		Same as on the left
Hidenori Nishi		Independent Director		Same as on the left
Keiya Ozawa		Independent Director		Same as on the left
2. Directors who serve as Audit and Supervisory Committee Members
Name		New position		Current position
Takanori Shibazaki		Director (Full-time Audit and Supervisory		Same as on the left
	Committee Member)
Masaichi Nakamura		Independent Director (Audit and Supervisory		Same as on the left
	Committee Member)
Soichiro Uno		Independent Director (Audit and Supervisory		Same as on the left
	Committee Member)

About Terumo

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.